Nano-Biological Contrast Agent Platform for MRI Imaging
NANO-IMAGING aims to develop customizable, safe, and tissue-specific MRI contrast agents using metal-protein hybrid nanostructures to enhance diagnostic imaging efficiency.
Projectdetails
Introduction
NANO-IMAGING proposes the elucidation of the potential of a metal-protein hybrid nanostructure as a platform for the development of tissue-specific positive Magnetic Resonance Imaging (MRI) contrast agents. This proposal builds on the large demand for MRI examinations worldwide, the health concerns raised by available contrast agents, and the little choice of tissue-specific contrast agents available to clinical practitioners.
Unique Value Proposition
The unique value proposition of NANO-IMAGING is a safe, bright, and tissue-specific MRI contrast agent. This is made possible due to the purposely designed structure and composition of the nanostructure and its tissue-targeting properties.
Proposed Solution
The proposed solution, based on proprietary technology, allows for:
- Control of the nanomaterial properties.
- Straightforward customization of targeting moieties.
Having observed the basic principles of the technology, formulated the concept behind the idea, and conducted in-vitro experiments that prove the consistency of our revolutionary approach, we now want to further the technology towards clinical practice by testing it in-vivo.
Goals and Impact
By leveraging the platform nature of this solution and our capacity to tune the targeting properties of the nanostructure, we aim to provide:
- A simple, tunable, and affordable development platform for the fabrication of biocompatible, tissue-specific MRI contrast agents à la carte.
Therefore, the successful outcome of this project will help realize the breakthrough and innovation potential of this solution for the fast and cost-effective development of a growing portfolio of tissue-specific MRI contrast agents. This will address a current societal challenge in health by satisfying the present demand for efficient, safe, and tissue-specific contrast agents for diagnosis.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 31-3-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MAGNIFICO-Pre-commercialization of multifunctional targeted MRI-contrast enhancing agents for brain researchThis project aims to enhance MRI's capabilities for brain disease research by developing targeted fluorescent contrast agents and engineering cells for improved in vivo imaging. | ERC Proof of... | € 150.000 | 2022 | Details |
Tailored Bacterial Magnetic Nanoparticles For Biomedical ImagingThis project aims to revolutionize biomedical applications by developing high-quality, biocompatible magnetic iron oxide nanoparticles using genetically engineered microbes for enhanced functionality and sustainability. | ERC Proof of... | € 150.000 | 2023 | Details |
Revealing liver micrometastases in vivo using ultra-high definition MRIMicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights. | ERC Starting... | € 1.998.456 | 2025 | Details |
Functional Nanoscale TherapeuticsDevelop functional hybrid nanoscale medicines to enhance intracellular delivery of mRNA and combat nanoscale pathogens, aiming for advanced therapies against diseases like cancer. | ERC Advanced... | € 2.499.796 | 2024 | Details |
Signal-enhanced MRI contrast agents for neurodegenerationThis project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents. | ERC Proof of... | € 150.000 | 2022 | Details |
MAGNIFICO-Pre-commercialization of multifunctional targeted MRI-contrast enhancing agents for brain research
This project aims to enhance MRI's capabilities for brain disease research by developing targeted fluorescent contrast agents and engineering cells for improved in vivo imaging.
Tailored Bacterial Magnetic Nanoparticles For Biomedical Imaging
This project aims to revolutionize biomedical applications by developing high-quality, biocompatible magnetic iron oxide nanoparticles using genetically engineered microbes for enhanced functionality and sustainability.
Revealing liver micrometastases in vivo using ultra-high definition MRI
MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.
Functional Nanoscale Therapeutics
Develop functional hybrid nanoscale medicines to enhance intracellular delivery of mRNA and combat nanoscale pathogens, aiming for advanced therapies against diseases like cancer.
Signal-enhanced MRI contrast agents for neurodegeneration
This project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Revolutionizing Spatial Biology with a cutting-edge Multi-Scale Imaging platformThe NanoSCAN project aims to develop the SAFe-nSCAN platform for high-resolution 3D tissue analysis, enhancing molecular profiling and advancing personalized therapies in immuno-oncology. | EIC Transition | € 2.489.162 | 2023 | Details |
An AI powered turn-key solution for MRI based interventional cardiologyNano4Imaging aims to deliver TRACKR, a B2B platform enhancing MRI-guided interventional radiology with nano-coatings and real-time tracking software for commercial device makers. | EIC Accelerator | € 2.482.709 | 2023 | Details |
Single Molecule Nuclear Magnetic Resonance Microscopy for Complex Spin SystemsThis project aims to enhance NMR sensitivity to single molecules using scanning probe microscopy, enabling groundbreaking insights in nanotechnology and impacting NMR and SPM markets. | EIC Pathfinder | € 2.994.409 | 2023 | Details |
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic careMIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally. | EIC Transition | € 2.495.127 | 2022 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Revolutionizing Spatial Biology with a cutting-edge Multi-Scale Imaging platform
The NanoSCAN project aims to develop the SAFe-nSCAN platform for high-resolution 3D tissue analysis, enhancing molecular profiling and advancing personalized therapies in immuno-oncology.
An AI powered turn-key solution for MRI based interventional cardiology
Nano4Imaging aims to deliver TRACKR, a B2B platform enhancing MRI-guided interventional radiology with nano-coatings and real-time tracking software for commercial device makers.
Single Molecule Nuclear Magnetic Resonance Microscopy for Complex Spin Systems
This project aims to enhance NMR sensitivity to single molecules using scanning probe microscopy, enabling groundbreaking insights in nanotechnology and impacting NMR and SPM markets.
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.